In addition, we reviewed previously published cases of ruxolitinib treatment for adult-onset DM and JAK2 V617F mutation with adult idiopathic inflammatory myopathy(IIM) to broaden our understanding. The gene discussed is JAK2; the disease is dermatomyositis.